On September 8, 2026, X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the U.S. Food and Drug Administration regarding the global 4WARD Phase 3 clinical trial for mavorixafor. The FDA agreed to reduce the required sample size from 176 to 126 participants while maintaining adequate statistical power for co-primary endpoints: reduction in annualized infection rate and positive absolute neutrophil count response. Management expects enrollment completion by year-end 2026 and topline data release in the first half of 2028. X4 Pharmaceuticals is a biotechnology company focused on developing therapies for rare hematology diseases.

X4 Pharmaceuticals, Inc. appointed Kelly Gold as a Class II director and Audit Committee member, effective July 1, 2026. This appointment increased the Board of Directors from five to six members. X4 Pharmaceuticals, Inc. is a biopharmaceutical company.